Optimal Dose of Omeprazole After Endoscopic Treatment of Bleeding Peptic Ulcers
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Bleeding peptic ulcers are one of the major causes of morbidity and mortality for hospital emergency admissions.The initial treatment is endoscopic therapy followed by intravenous omeprazole. However the optimal dosage of omeprazole is not known. We conducted this study to find out the optimal dosage in such clinical scenario.
| Condition | Intervention | Phase |
|---|---|---|
|
Bleeding Peptic Ulcers Disease |
Drug: Omeprazole |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Intravenous Infusion of High Dose Omeprazole Versus Regular Dose Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers |
- Re-bleeding rate after endoscopic treatment of bleeding peptic ulcers [ Time Frame: 30 days after endoscopic therapy ] [ Designated as safety issue: Yes ]
- Surgery, Death and Length of hospital stay [ Time Frame: 30 days after endoscopic thearpy ] [ Designated as safety issue: Yes ]
| Enrollment: | 126 |
| Study Start Date: | July 2004 |
| Study Completion Date: | November 2007 |
| Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 2
regular dose versus high dose
|
Drug: Omeprazole
intravenous 80mg bolus followed by 8mg / hr for 3 days
Other Name: intravenous 40 mg om for 3 days
|
Detailed Description:
Introduction
Peptic ulcer bleeding (PUB) is a common and life threatening condition. Intravenous infusion of high dose omeprazole (80mg as bolus followed by 8 mg/hr for 72 hours ie 652 mg/72 hrs) after endoscopic therapy resulted in greater reductions of re-bleeding than did placebo. Thus the above regime became our departmental protocol. However, there is some evidence that both high dose and a regular dose of omeprazole (40mg once a day followed by a saline infusion ie 120mg/72 hrs) would be equally effective. We calculated that high dose regimen is about S$ 500 more expensive. The aim of our study is to determine the equivalence of both regimes in preventing re-bleeding rate (primary end-point), surgery and mortality in PUB patients.
Study design This is a single institution prospective randomized double-blind study. All patient with PUB (Forrest classification I, IIa and IIb: spurting or oozing bleeding, visible vessels and clot) had endoscopic treatments (adrenaline injection and/or heater probe). After successful endoscopic hemostasis, patients are randomized to receive a high or regular dose of omeprazole infusion. After 72 hours, both groups of patients are given oral omeprazole 40mg daily for 4 weeks. All patients are evaluated at the clinic at the end of 4 weeks. The primary end-point is rebleeding. Other secondary endpoints measured are surgery, duration of hospital stay and death.
Eligibility| Ages Eligible for Study: | 18 Years to 90 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Above 21 year old
- OGD done within 48 hrs of admission
- No recent upper GIT surgery past one month
- Forrest Type I, IIa & IIb ulcer (Type Ia: Spurting, Ib:Oozing, IIa: Visible vessel, IIb: Clot)
- Non-malignant ulcer
- Informed consent taken
Exclusion Criteria:
- Impaired hepatic function
- Pregnancy
- Lactation
- Concomitant medication (warfarin, diazepam, phenytoin, chlarithromycin, cimetidine and digoxin)
- Underlying malignancy
Contacts and Locations| Singapore | |
| Singapore General Hospital | |
| Outram Road, Singapore, Outram Road, Singapore, 169608 | |
| Department of Surgery, Singapore General Hospital | |
| Outram Road, Singapore, Outram road, Singapore, 169608 | |
| Singapore General Hospital | |
| Singapore, Outram Road, Singapore, 169608 | |
| Department of Surgery, Singapore General Hospital | |
| Singapore, Outram road, Singapore, 169608 | |
| Principal Investigator: | Weng Hoong Chan, MBBS, FRCS | Singapore General Hospital |
| Principal Investigator: | Weng Hoong Chan, MBBS, FRCS | Department of Surgery, Singapore General Hospital |
More Information
No publications provided by Singapore General Hospital
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Dr weng Hoong Cha, Senior Consultant, department of Surgeey, Singapore General Hospital, Singapore General hospital |
| ClinicalTrials.gov Identifier: | NCT00519519 History of Changes |
| Other Study ID Numbers: | 78:10/03-098 |
| Study First Received: | August 21, 2007 |
| Last Updated: | October 29, 2008 |
| Health Authority: | Singapore: Health Sciences Authority |
Keywords provided by Singapore General Hospital:
|
Rebleeding after endoscopic therapy |
Additional relevant MeSH terms:
|
Hemorrhage Peptic Ulcer Peptic Ulcer Hemorrhage Ulcer Pathologic Processes Duodenal Diseases Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases |
Stomach Diseases Gastrointestinal Hemorrhage Omeprazole Anti-Ulcer Agents Gastrointestinal Agents Therapeutic Uses Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013